Welcome to our dedicated page for Inovio Pharmaceuticals news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceuticals stock.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a pioneering United States-based biotechnology company dedicated to combating cancers and infectious diseases through DNA medicines. The company's innovative approach harnesses active DNA-based immunotherapies and vaccines to both treat and prevent these conditions.
Inovio's core technology revolves around its DNA plasmids, which are small circular DNA molecules crafted to produce specific proteins to target and fight diseases, delivered via their proprietary CELLECTRA® electroporation devices. This technology enables the body to produce its own disease-fighting proteins and immune responses, without the need for traditional adjuvants or nanoparticles.
The company's flagship candidate, INO-3107, targets Recurrent Respiratory Papillomatosis (RRP), a chronic and rare disease caused by HPV-6 and HPV-11. Inovio has shown significant clinical progress with INO-3107, and after receiving Breakthrough Therapy designation and Orphan Drug designation from both the FDA and the European Commission, it is on track to submit a Biologics License Application (BLA) under the FDA's accelerated approval program. With successful clinical trials demonstrating a robust immune response and a reduction in the need for surgical interventions, INO-3107 stands as a potential game-changer for RRP patients.
In addition to INO-3107, Inovio's expansive product pipeline includes several other promising candidates in various stages of development. These include INO-3112 for HPV-16/18 positive head and neck cancer, INO-4201 as an Ebola vaccine booster, and INO-5401 for glioblastoma, showcasing the versatility and broad applicability of the company's DNA medicine platform.
Inovio has established numerous strategic partnerships and collaborations to enhance its research and development efforts. Key partners include Roche, MedImmune, the University of Pennsylvania, DARPA, Drexel University, NIH, and the U.S. Military HIV Research Program. These collaborations not only bolster Inovio's scientific capabilities but also facilitate the swift advancement of its clinical programs.
Financially, Inovio has maintained a disciplined approach to managing its resources. The company recently projected its cash runway to extend into the second quarter of 2025, following positive feedback from the FDA on the accelerated approval pathway for INO-3107. This financial stability is crucial as Inovio prepares for potential commercialization of its lead candidates.
Inovio's commitment to innovation and its effective strategic execution position it as a formidable player in the biopharmaceutical industry, dedicated to bringing groundbreaking DNA medicine solutions to market. For more information, visit www.inovio.com.
INOVIO Pharmaceuticals (NASDAQ: INO) and QIAGEN (NYSE: QGEN) have extended their partnership to develop liquid biopsy-based companion diagnostics utilizing next-generation sequencing (NGS) technology. This collaboration focuses on a diagnostic test to identify women likely to benefit from INOVIO's VGX-3100, an immunotherapy for advanced cervical dysplasia linked to HPV. VGX-3100 is currently undergoing two Phase 3 trials, aiming to be the first non-surgical treatment for this condition. QIAGEN's expertise in bioinformatics will enhance the predictive capability of the diagnostic test.
QIAGEN and INOVIO Pharmaceuticals have extended their partnership with a master collaboration agreement to develop liquid biopsy-based diagnostic products utilizing next-generation sequencing (NGS) technology. The initial project will focus on a diagnostic test for identifying women who may benefit from VGX-3100, INOVIO's immunotherapy for advanced cervical dysplasia linked to HPV. This test will leverage QIAGEN’s bioinformatics to enhance INOVIO’s biomarker signature and will be developed for the Illumina NextSeq 550Dx platform, following a partnership established in 2019.
INOVIO (NASDAQ:INO) has initiated the first Phase 1B clinical trial for its DNA vaccine candidate, INO-4500, aimed at combatting Lassa fever in Ghana. This marks the first human trial for a Lassa fever vaccine in West Africa, an area heavily impacted by the disease. The trial, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), will involve 220 participants to assess safety and immunogenicity. INO-4500 has shown promising immune responses in prior trials. Successful advancement could lead to emergency stockpiling post-Phase 2 evaluation.
INOVIO (NASDAQ: INO) will release its fourth quarter and year-end 2020 financial results on March 1, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide updates on the company's DNA Medicines Platform, particularly its COVID-19 vaccine development. INOVIO, a pioneer in DNA medicines, is advancing clinical trials for its lead candidate VGX-3100, which targets precancerous cervical dysplasia linked to high-risk HPV types 16 and 18.
INOVIO Pharmaceuticals (Nasdaq: INO) has successfully closed its underwritten public offering of 20,355,000 shares at $8.50 each, generating approximately $173 million in gross proceeds. This includes an additional 2,655,000 shares purchased due to the underwriters' full exercise of their option. The offering was executed under an automatically effective shelf registration statement filed with the SEC on January 20, 2021. Funds from this offering are expected to enhance INOVIO's capabilities in developing DNA medicines for infectious diseases and cancer.
INOVIO Pharmaceuticals (Nasdaq: INO) announced the pricing of an underwritten public offering of 17.7 million shares of common stock at $8.50 per share, expected to yield approximately $150.5 million in gross proceeds. The offering includes an option for underwriters to purchase an additional 2.655 million shares. Proceeds will support clinical development, including INO-4800, and general corporate purposes. The offering is anticipated to close on January 25, 2021, following customary conditions. This offering was registered with the SEC and aims to advance INOVIO's DNA medicine pipeline.
INOVIO Pharmaceuticals announced a public offering of $150 million in common stock, with plans to grant underwriters a 30-day option for an additional 15%. Proceeds will fund clinical development, specifically for INO-4800, and cover general corporate expenses. BofA Securities, Jefferies, and Cantor are managing the offering. This follows their shelf registration statement filed with the SEC, effective January 20, 2021. The offering is subject to market conditions, and there are no guarantees regarding its completion.
INOVIO (NASDAQ: INO) announced promising results from a Phase 2 trial of VGX-3100 for HPV-16/18-associated vulvar dysplasia. At six months post-treatment, 63% of participants showed a clinically significant reduction in lesions, a stark contrast to the typical 2% spontaneous resolution rate. Notably, 15% of participants had resolved lesions with no detectable virus. The trial confirmed VGX-3100's safety, with no severe adverse events reported. INOVIO plans to advance to Phase 3 development based on these results, representing a potential breakthrough in non-surgical treatment options.
INOVIO (NASDAQ: INO) announces a collaboration with Advaccine Biopharmaceuticals to commercialize its COVID-19 DNA vaccine candidate INO-4800 in Greater China, including Mainland China, Hong Kong, Macao, and Taiwan. Advaccine will exclusively develop, manufacture, and market INO-4800 for an upfront payment of $3 million and potential milestone payments totalling $108 million. INOVIO will receive royalties on annual net sales. The collaboration leverages Advaccine’s manufacturing capabilities and clinical data to support INOVIO’s global regulatory filings while advancing the Phase 2 clinical trial of INO-4800 in China, involving 640 subjects.
INOVIO (NASDAQ: INO) has published peer-reviewed Phase 1 clinical data for its COVID-19 DNA vaccine candidate, INO-4800, in EClinicalMedicine. The study involved 40 healthy adults and demonstrated that INO-4800 generated an immune response in all participants with favorable safety, showing only six minor adverse events. The vaccine maintains stability at room temperature over a year, aiding global distribution. INOVIO is advancing to Phase 2 trials, funded by the U.S. Department of Defense, further validating the vaccine's safety and efficacy in upcoming segments.
FAQ
What is the current stock price of Inovio Pharmaceuticals (INO)?
What is the market cap of Inovio Pharmaceuticals (INO)?
What is Inovio Pharmaceuticals' primary focus?
What is INO-3107?
What is the CELLECTRA® device?
Who are some of Inovio’s key partners?
What financial outlook has Inovio projected?
What is INO-3112?
How does Inovio's DNA medicines platform work?
What are some of Inovio’s recent achievements?
Where can I find more financial information about Inovio?
What is Inovio's approach to commercialization?
